OraSure sell-off on 23andMe warning letter an overreaction, says Citigroup Citigroup believes the sell-off in shares of OraSure after its customer 23andMe received a warning letter from the FDA was an overreaction. Citi says 23andMe represents less than 5% of total company sales. The firm views Monday's sell off as a buying opportunity.
News For OSUR From The Last 14 Days
Check below for free stories on OSUR the last two weeks.
OraSure price target raised to $10 from $7.50 at Raymond James Raymond James raised OraSure's price target to $10 from $7.50 to reflect HCV and DNA Genotek drivers, accretive M&A, and disciplined spending. Shares are Outperform rated.